Santhera Pharmaceuticals Holding AG (SPHDF)
OTCMKTS · Delayed Price · Currency is USD
12.28
0.00 (0.00%)
Oct 20, 2025, 8:00 PM EDT
SPHDF Revenue
Santhera Pharmaceuticals Holding AG had revenue of 24.01M CHF in the half year ending June 30, 2025, with 509.62% growth. This brings the company's revenue in the last twelve months to 49.02M, down -56.85% year-over-year. In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M, down -62.17%.
Revenue (ttm)
49.02M CHF
Revenue Growth
-56.85%
P/S Ratio
2.79
Revenue / Employee
624.41K CHF
Employees
79
Market Cap
171.91M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
| Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
| Dec 31, 2022 | 7.47M | 9.07M | -568.53% |
| Dec 31, 2021 | -1.60M | -16.60M | -110.63% |
| Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Santhera Pharmaceuticals Holding AG News
- 13 days ago - Santhera Partners With Biomedica To Distribute Agamree In Russia - Nasdaq
- 19 days ago - Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy - Nasdaq
- 23 days ago - Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track? - Nasdaq
- 7 weeks ago - Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India - GlobeNewsWire
- 2 months ago - Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - GlobeNewsWire
- 6 months ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha